Beatrice Engelmann1, Julia Bischof1, Anne-Luise Dirk2, Nele Friedrich3, Elke Hammer1, Thomas Thiele4, Dagmar Führer5, Georg Homuth1, Georg Brabant2, Uwe Völker1. 1. Interfaculty Institute for Genetics and Functional Genomics, Greifswald, Germany. 2. Experimental and Clinical Endocrinology, Med Clinic I, University of Lübeck, Lübeck, Germany. 3. Institute for Clinical Chemistry and Laboratory Medicine, Greifswald, Germany. 4. Institute for Immunology and Transfusion Medicine, University Medicine Greifswald, Greifswald, Germany. 5. Clinic for Endocrinology and Metabolic Disorders, University Clinics Essen, Essen, Germany.
Abstract
BACKGROUND: Hyperthyroidism is known to induce a hypercoagulable state. It stimulates plasma levels of procoagulative factors and reduces fibrinolytic activity. So far most of the data have been derived from patients with endogenous hyperthyroidism with a wide variability in the underlying pathogenesis and severity of the disease. OBJECTIVES: In this study we experimentally induced thyrotoxicosis in healthy volunteers to explore the effects of thyroxine excess on the plasma proteome. Using a shotgun proteomics approach, the abundance of plasma proteins was monitored before, during and after thyrotoxicosis. METHODS: Sixteen healthy male subjects were sampled at baseline, 4 and 8 weeks under 250 µg/day thyroxine p.o., as well as 4 and 8 weeks after stopping the application. Plasma proteins were analyzed after depletion of 6 high-abundance proteins (MARS6) by LC-ESI-MS/MS mass spectrometry. Mass spectrometric raw data were processed using a label-free, intensity-based workflow. Subsequently, the linear dependence between protein abundances and fT4 levels were calculated using a Pearson correlation. RESULTS: All subjects developed biochemical thyrotoxicosis, and this effect was reversed within the first 4 weeks of follow-up. None of the volunteers noticed any subjective symptoms. Levels of 10 proteins involved in the coagulation cascade specifically correlated with fT4, supporting an influence of thyroid hormone levels on blood coagulation even at nonpathological levels. CONCLUSIONS: The results suggest that experimental thyrotoxicosis exerts selective and specific thyroxine-induced effects on coagulation markers. Our study design allows assessment of thyroid hormone effects on plasma protein levels without secondary effects of other diseases or therapies.
BACKGROUND:Hyperthyroidism is known to induce a hypercoagulable state. It stimulates plasma levels of procoagulative factors and reduces fibrinolytic activity. So far most of the data have been derived from patients with endogenous hyperthyroidism with a wide variability in the underlying pathogenesis and severity of the disease. OBJECTIVES: In this study we experimentally induced thyrotoxicosis in healthy volunteers to explore the effects of thyroxine excess on the plasma proteome. Using a shotgun proteomics approach, the abundance of plasma proteins was monitored before, during and after thyrotoxicosis. METHODS: Sixteen healthy male subjects were sampled at baseline, 4 and 8 weeks under 250 µg/day thyroxine p.o., as well as 4 and 8 weeks after stopping the application. Plasma proteins were analyzed after depletion of 6 high-abundance proteins (MARS6) by LC-ESI-MS/MS mass spectrometry. Mass spectrometric raw data were processed using a label-free, intensity-based workflow. Subsequently, the linear dependence between protein abundances and fT4 levels were calculated using a Pearson correlation. RESULTS: All subjects developed biochemical thyrotoxicosis, and this effect was reversed within the first 4 weeks of follow-up. None of the volunteers noticed any subjective symptoms. Levels of 10 proteins involved in the coagulation cascade specifically correlated with fT4, supporting an influence of thyroid hormone levels on blood coagulation even at nonpathological levels. CONCLUSIONS: The results suggest that experimental thyrotoxicosis exerts selective and specific thyroxine-induced effects on coagulation markers. Our study design allows assessment of thyroid hormone effects on plasma protein levels without secondary effects of other diseases or therapies.
Authors: J M W Hooper; D J F Stuijver; S M Orme; B van Zaane; K Hess; V E Gerdes; F Phoenix; P Rice; K A Smith; S H Alzahrani; K F Standeven; R A Ajjan Journal: J Clin Endocrinol Metab Date: 2012-02-29 Impact factor: 5.958
Authors: J Debeij; B van Zaane; O M Dekkers; C J M Doggen; J W A Smit; A P van Zanten; D P M Brandjes; H R Büller; V E A Gerdes; F R Rosendaal; S C Cannegieter Journal: J Thromb Haemost Date: 2014-06 Impact factor: 5.824
Authors: Elke Hammer; Michelle Goritzka; Sabine Ameling; Katrin Darm; Leif Steil; Karin Klingel; Christiane Trimpert; Lars R Herda; Marcus Dörr; Heyo K Kroemer; Reinhard Kandolf; Alexander Staudt; Stephan B Felix; Uwe Völker Journal: J Proteome Res Date: 2011-04-01 Impact factor: 4.466
Authors: Danka J F Stuijver; Bregje van Zaane; Erica Romualdi; Dees P M Brandjes; Victor E A Gerdes; Alessandro Squizzato Journal: Thromb Haemost Date: 2012-09-26 Impact factor: 5.249
Authors: B Van Zaane; A Squizzato; J Debeij; O M Dekkers; J C M Meijers; A P Van Zanten; H R Büller; V E A Gerdes; S C Cannegieter; D P M Brandjes Journal: J Thromb Haemost Date: 2011-09 Impact factor: 5.824
Authors: Maik Pietzner; Beatrice Engelmann; Tim Kacprowski; Janine Golchert; Anna-Luise Dirk; Elke Hammer; K Alexander Iwen; Matthias Nauck; Henri Wallaschofski; Dagmar Führer; Thomas F Münte; Nele Friedrich; Uwe Völker; Georg Homuth; Georg Brabant Journal: BMC Med Date: 2017-01-09 Impact factor: 8.775
Authors: Assim A Alfadda; Hicham Benabdelkamel; Afshan Masood; Anwar A Jammah; Aishah A Ekhzaimy Journal: Int J Mol Sci Date: 2018-01-01 Impact factor: 5.923
Authors: Maik Pietzner; Josef Köhrle; Ina Lehmphul; Kathrin Budde; Gabi Kastenmüller; Georg Brabant; Henry Völzke; Anna Artati; Jerzy Adamski; Uwe Völker; Matthias Nauck; Nele Friedrich; Georg Homuth Journal: Thyroid Date: 2019-11-11 Impact factor: 6.568